论文部分内容阅读
Objective: To explore the effects and mechanisms of poly(ADP-ribose) polymerase(PARP) inhibitor 3-aminobenzamide on nerve lesions in streptozotocin-diabetic rats. Methods: Experimental rats were divided into normal control group(NC group), diabetic control group(DC group)and diabetic group treated with 3-aminobenzamide(DT group).Nerve conduction velocity (NCV),serum superoxide dismutase (SOD) activity and serum malondialdehyde (MDA) concentration,phosphocreatine (Pcr),creatine (Cr) concentration in sciatic nerves were evaluated after 4 weeks. Results: SOD,Pcr activity,and NCV were higher (P < 0.05) and MDA concentration were significantly lower in DT group, compared with DC group (P < 0.01). Meanwhile, ATP and Cr in sciatic nerves were similar in DT group, compared with DC group (P > 0.05). Conclusion: 3-aminobenzamide could alleviate the established functional and metabolic abnormalities of early DPN in the streptozotocin-induced diabetic rat models,which provided a novel approach for prevention and treatment of diabetic neuropathy.
Objective: To explore the effects and mechanisms of poly (ADP-ribose) polymerase (PARP) inhibitor 3-aminobenzamide on nerve lesions in streptozotocin-diabetic rats. Methods: Experimental rats were divided into normal control group (NC group) (DC group) and diabetic group treated with 3-aminobenzamide (DT group) .Nerve conduction velocity (NCV), serum superoxide dismutase (SOD) activity and serum malondialdehyde (MDA) concentration, phosphocreatine Results: SOD, Pcr activity, and NCV were higher (P <0.05) and MDA concentrations were significantly lower in DT group, compared with DC group (P <0.01). Meanwhile, ATP and Cr in sciatic nerves were similar in DT group, compared with DC group (P> 0.05). Conclusion: 3-aminobenzamide could alleviate the established functional and metabolic abnormalities of early DPN in the streptozotocin-induced diabetic rat models, which provided a novel approach for prevention and treatment of diabetic neuropathy.